recall – Page 2

Microdosing candy-linked illnesses double; possible recall in “discussions”

CDC, chocolate, cones, diamond shruumz, fda, gummies, intubation, microdosing, outbreak, psychedelic, recall, Science, seizures / Paul Patrick / June 20, 2024

No recall —

Of the 26 cases identified so far, 25 sought medical care and 16 were hospitalized.

Beth Mole – Jun 20, 2024 6: 16 pm UTC

Cases of illnesses linked to microdosing candies have more than doubled, with reports of seizures and the need for intubation, mechanical ventilation, and intensive care stays. But, there remains no recall of the products—microdosing chocolates, gummies, and candy cones by Diamond Shruumz—linked to the severe and life-threatening illnesses. In the latest update from the Food and Drug Administration late Tuesday, the agency said that it “has been in contact with the firm about a possible voluntary recall, but these discussions are still ongoing.”

In the update, the FDA reported 26 cases across 16 states, up from 12 cases in eight states last week. Of the 26 reported cases, 25 sought medical care and 16 were hospitalized. No deaths have been reported.

Last week, the Centers for Disease Control and Prevention released a health alert about the candies. The agency noted that as of June 11, the people sickened after eating Diamond Shruumz candies presented to health care providers with a host of severe symptoms. Those include: central nervous system depression with sedation, seizures, muscle rigidity, clonus (abnormal reflex responses), tremor, abnormal heart rate (bradycardia or tachycardia), abnormal blood pressure (hypotension or hypertension), gastrointestinal effects (nausea, vomiting, or abdominal pain), skin flushing, diaphoresis (excessive sweating), and metabolic acidosis with increased anion gap (an acid-based disorder linked to poisonings).

At the time of the CDC alert, 10 patients had been hospitalized, and “several required intubation, mechanical ventilation, and admission to an intensive care unit,” the agency reported.

It remains unclear what ingredient in the candies could be causing the poisonings. The FDA reports that it has worked with state partners to collect multiple samples of Diamond Shruumz products so they can be analyzed for potential toxic components. That analysis is still ongoing, the agency said.

Diamond Shruumz has not responded to multiple requests for comment from Ars.

Untold toxic ingredients

Diamond Shruumz does not list the ingredients of its products on its website. They are sold as “microdosing” candies, a term that typically suggests a small amount of a psychedelic compound is present. The company describes its chocolates, gummies, and cones as “trippy,” “psychedelic,” and “hallucinogenic,” and also claims they contain a “primo proprietary blend of nootropic and functional mushrooms.” But, it’s unclear what, if any, psychoactive compound is present in the candies.

The CDC notes that products like these “might contain undisclosed ingredients, including illicit substances, other adulterants, or potentially harmful contaminants that are not approved for use in food.”

Diamond Shruumz posted documents on its website from third-party laboratories claiming to indicate that the candies do not contain the most notable mushroom-derived psychedelic compound, psilocybin. The reports also indicate that some of the products do not contain cannabinoids or compounds from the hallucinogenic Amanita muscaria mushroom. Additionally, the company said in a blog post that its products contain a blend of Lion’s mane, Reishi, and Chaga mushrooms, but these are all non-hallucinogenic mushrooms used in herbal and traditional medicines and supplements.

In recent decades, hundreds of new synthetic psychoactive substances have hit the market in such products, including many new phenethylamines and tryptamines, which are chemically related to LSD and psilocybin. Some experts and members of the psychedelic community have speculated that Diamond Shruumz products could potentially contain one of the more popular tryptamines, 4-AcO-DMT, often pronounced “4-akko-DMT,” and also known as 4- acetoxy-N,N-dimethyltryptamine, O-acetylpsilocin, or psilacetin. According to a qualitative 2020 study, users describe 4-AcO-DMT as producing effects similar to psilocybin, but without some of the unpleasant side effects noted with natural mushrooms, such as nausea. Animal experiments have confirmed that 4-AcO-DMT appears to produce psilocybin-like effects.

Still, it’s unclear if such ingredients could explain the symptoms seen in the current outbreak. Though clinical data on 4-AcO-DMT is scant, it has not been linked to such severe symptoms. On the other hand, some novel synthetic compounds, such as Dox and NBOMe, often misrepresented as LSD, are considered dangerous. For instance, NBOMe compounds (N-methoxybenzyl, also called N-bombs or 251), first discovered in 2003, have been linked to overdoses and deaths. In the scientific literature, they’ve been linked to “unpleasant hallucinations, panic, agitation, hypertension, seizures, acute psychosis, and/or excited delirium that can result in cardiac arrest,” according to the 2020 study.

Microdosing candy-linked illnesses double; possible recall in “discussions” Read More »

Microsoft delays Recall again, won’t debut it with new Copilot+ PCs after all

another setback —

Recall will go through Windows Insider pipeline like any other Windows feature.

Andrew Cunningham – Jun 14, 2024 2: 40 am UTC

Recall is part of Microsoft's Copilot+ PC program. — Enlarge / Recall is part of Microsoft’s Copilot+ PC program.

Microsoft

Microsoft will be delaying its controversial Recall feature again, according to an updated blog post by Windows and Devices VP Pavan Davuluri. And when the feature does return “in the coming weeks,” Davuluri writes, it will be as a preview available to PCs in the Windows Insider Program, the same public testing and validation pipeline that all other Windows features usually go through before being released to the general populace.

Recall is a new Windows 11 AI feature that will be available on PCs that meet the company’s requirements for its “Copilot+ PC” program. Copilot+ PCs need at least 16GB of RAM, 256GB of storage, and a neural processing unit (NPU) capable of at least 40 trillion operations per second (TOPS). The first (and for a few months, only) PCs that will meet this requirement are all using Qualcomm’s Snapdragon X Plus and X Elite Arm chips, with compatible Intel and AMD processors following later this year. Copilot+ PCs ship with other generative AI features, too, but Recall’s widely publicized security problems have sucked most of the oxygen out of the room so far.

The Windows Insider preview of Recall will still require a PC that meets the Copilot+ requirements, though third-party scripts may be able to turn on Recall for PCs without the necessary hardware. We’ll know more when Recall makes its reappearance.

Why Recall was recalled

Recall works by periodically capturing screenshots of your PC and saving them to disk, and scanning those screenshots with OCR to make a big searchable text database that can help you find anything you had previously viewed on your PC.

The main problem, as we confirmed with our own testing, was that all of this was saved to disk with no additional encryption or other protection and was easily viewable and copyable by pretty much any user (or attacker) with access to the PC. Recall was also going to be enabled by default on Copilot+ PCs despite being a “preview,” meaning that users who didn’t touch the default settings were going to have all of this data recorded by default.

This was the version of Recall that was initially meant to ship out to reviewers this week on the first wave of Copilot+ PCs from Microsoft and other PC companies. After security researcher Kevin Beaumont publicized these security holes in that version of Recall, the company promised to add additional encryption and authentication protections and to disable Recall by default. These tweaks would have gone out as an update to the first shipments of Copilot+ PCs on June 18 (reviewers also wouldn’t get systems before June 18, a sign of how much Microsoft was rushing behind the scenes to implement these changes). Now Recall is being pushed back again.

A report from Windows Central claims that Recall was developed “in secret” and that it wasn’t even distributed widely within Microsoft before it was announced, which could explain why these security issues weren’t flagged and fixed before the feature showed up in a publicly available version of Windows.

Microsoft’s Recall delay follows Microsoft President Brad Smith’s testimony to Congress during a House Committee on Homeland Security hearing about the company’s “cascade of security failures” in recent months. Among other things, Smith said that Microsoft would commit to prioritizing security issues over new AI-powered features as part of the company’s recently announced Secure Future Initiative (SFI). Microsoft has also hired additional security personnel and tied executive pay to meeting security goals.

“If you’re faced with the tradeoff between security and another priority, your answer is clear: Do security,” wrote Microsoft CEO Satya Nadella in an internal memo about the SFI announcement. “In some cases, this will mean prioritizing security above other things we do, such as releasing new features or providing ongoing support for legacy systems.”

Recall has managed to tie together all the big Windows and Microsoft stories from the last year or two: the company’s all-consuming push to quickly release generative AI features, its security failures and subsequent promises to do better, and the general degradation of the Windows 11 user interface with unwanted apps, ads, reminders, account sign-in requirements, and other cruft.